Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A wave of updated price targets from Wall Street analysts is prompting investors to reassess Diana Shipping Inc. The shifting forecasts reflect changing views on dry bulk shipping fundamentals and the company's strategic position, moving the stock's story beyond recent quarters.
CNBC's Jim Cramer questions Meta's direction, citing investor skepticism over its AI strategy and spending. Yet strong Q4 earnings reveal a more complex financial picture, sparking debate on Wall Street.
While Exelon's recent earnings beat expectations, the utility giant continues to face investor skepticism over its long-term growth trajectory. Wall Street maintains a guarded optimism, but the stock's performance tells a more nuanced story.
President Trump nominates Kevin Warsh, a former Fed governor with Wall Street ties, to succeed Jerome Powell as Federal Reserve Chair. His confirmation faces scrutiny amid questions over monetary policy direction and the central bank's political independence.
While rising crude prices have lifted Occidental Petroleum's stock recently, a mixed earnings performance and a predominantly 'Hold' rating from Wall Street signal lingering skepticism about its near-term trajectory.
A proposed near-zero payment increase for Medicare Advantage plans by the Trump administration has blindsided Wall Street, erasing billions in market value and raising fears of a prolonged downturn for major health insurers.
OFG Bancorp (OFG) is drawing renewed attention from Wall Street as analysts recalibrate their price targets, signaling a potential shift in the bank's investment narrative. The adjustments reflect evolving views on the Puerto Rico-based lender's strategic positioning, risk exposure, and emerging growth opportunities in a changing economic landscape.
President Trump's nomination of former Fed governor Kevin Warsh to lead the central bank has sparked immediate concerns on Wall Street about political influence over monetary policy, setting the stage for a contentious Senate confirmation battle.
SanDisk's stock surged after the data storage giant issued a blockbuster third-quarter outlook, far exceeding Wall Street expectations. The company credited soaring demand from artificial intelligence applications and announced a major extension to a key supply agreement, highlighting the intense competition for memory chips in the AI era.
President Donald Trump's nomination of Kevin Warsh to lead the Federal Reserve sets the stage for a potential pivot in U.S. monetary policy, placing a seasoned yet controversial figure with deep Wall Street ties at the helm.
Progress Software Corporation (PRGS) sees bullish sentiment from Wall Street following its Q4 2025 results, with analysts highlighting its growing recurring revenue and strategic positioning in the enterprise software market.
American Express reported a 10.6% year-over-year revenue increase to $17.57 billion for the fourth quarter of 2025, yet missed Wall Street's sales expectations. Earnings per share of $3.53 met analyst consensus estimates.
SoFi Technologies smashed Wall Street's Q4 2025 revenue and profit forecasts, sending its shares sharply higher. However, the digital finance leader's shockingly weak sales outlook for the coming quarter has injected significant uncertainty into its growth narrative.
A bold congressional proposal to cap credit card interest rates at 10% is drawing sharp criticism from Wall Street and raising fundamental questions about the future profitability of card issuers like American Express.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Wall Street firms Keefe Bruyette and BTIG have raised price targets on Core Scientific, citing the company's strategic shift from Bitcoin mining to high-performance computing infrastructure for AI as a key driver for future growth.
HSBC has upgraded Grab Holdings from Hold to Buy with a $6.20 price target, citing attractive valuation and intact growth drivers. The stock, already on some 'best buy' lists, has surged nearly 5% this week, with Wall Street analysts forecasting significant upside ahead of its Q4 earnings report.
Wall Street analysts have issued a revised price target for Zillow Group, signaling a recalibration of expectations around the online real estate giant's business model and competitive standing in a shifting market.
